-
1
-
-
84859899567
-
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
-
Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012;119(26):6198-208
-
(2012)
Blood
, vol.119
, Issue.26
, pp. 6198-6208
-
-
Walter, R.B.1
Appelbaum, F.R.2
Estey, E.H.3
Bernstein, I.D.4
-
2
-
-
84886825064
-
SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
-
Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122(8):1455-63
-
(2013)
Blood
, vol.122
, Issue.8
, pp. 1455-1463
-
-
Kung Sutherland, M.S.1
Walter, R.B.2
Jeffrey, S.C.3
-
3
-
-
0035524114
-
Improving the efficacy of antibody-based cancer therapies
-
Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1(2):118-29
-
(2001)
Nat Rev Cancer
, vol.1
, Issue.2
, pp. 118-129
-
-
Carter, P.1
-
4
-
-
26244466523
-
BiTEs: Bispecific antibody constructs with unique anti-tumor activity
-
Wolf E, Hofmeister R, Kufer P, et al. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005;10(18):1237-44
-
(2005)
Drug Discov Today
, vol.10
, Issue.18
, pp. 1237-1244
-
-
Wolf, E.1
Hofmeister, R.2
Kufer, P.3
-
5
-
-
79958041608
-
Bispecific antibodies engage T cells for antitumor immunotherapy
-
Choi BD, Cai M, Bigner DD, et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011;11(7):843-53
-
(2011)
Expert Opin Biol Ther
, vol.11
, Issue.7
, pp. 843-853
-
-
Choi, B.D.1
Cai, M.2
Bigner, D.D.3
-
6
-
-
84862251353
-
Symmetry breaking: Bispecific antibodies, the beginnings, and 50 years on
-
Riethmüller G. Symmetry breaking: Bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012;12:12
-
(2012)
Cancer Immun
, vol.12
, pp. 12
-
-
Riethmüller, G.1
-
7
-
-
67449156132
-
Bispecific T-cell engaging antibodies for cancer therapy
-
Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69(12):4941-4
-
(2009)
Cancer Res
, vol.69
, Issue.12
, pp. 4941-4944
-
-
Baeuerle, P.A.1
Reinhardt, C.2
-
8
-
-
84886809704
-
Tumor and T cell engagement by BiTE
-
Wickramasinghe D. Tumor and T cell engagement by BiTE. Discov Med 2013; 16(88):149-52
-
(2013)
Discov Med
, vol.16
, Issue.88
, pp. 149-152
-
-
Wickramasinghe, D.1
-
9
-
-
84871491706
-
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
-
Topp MS, Go'kbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7
-
(2012)
Blood
, vol.120
, Issue.26
, pp. 5185-5187
-
-
Topp, M.S.1
Gokbuget, N.2
Zugmaier, G.3
-
10
-
-
84876272598
-
Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) [abstract]
-
Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) [abstract]. Blood 2012;120(21):670
-
(2012)
Blood
, vol.120
, Issue.21
, pp. 670
-
-
Topp, M.S.1
Goekbuget, N.2
Zugmaier, G.3
-
11
-
-
84876116790
-
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
-
Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27(5):1107-15
-
(2013)
Leukemia
, vol.27
, Issue.5
, pp. 1107-1115
-
-
Aigner, M.1
Feulner, J.2
Schaffer, S.3
-
12
-
-
84897019168
-
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
-
Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123(3): 356-65
-
(2014)
Blood
, vol.123
, Issue.3
, pp. 356-365
-
-
Krupka, C.1
Kufer, P.2
Kischel, R.3
-
13
-
-
84897018823
-
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody AMG 330 against human AML
-
Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123(4): 554-61
-
(2014)
Blood
, vol.123
, Issue.4
, pp. 554-561
-
-
Laszlo, G.S.1
Gudgeon, C.J.2
Harrington, K.H.3
-
14
-
-
84860333177
-
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
-
Pollard JA, Alonzo TA, Loken M, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 2012;119(16):3705-11
-
(2012)
Blood
, vol.119
, Issue.16
, pp. 3705-3711
-
-
Pollard, J.A.1
Alonzo, T.A.2
Loken, M.3
-
15
-
-
79952282655
-
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
-
Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011;30(9): 1009-19
-
(2011)
Oncogene
, vol.30
, Issue.9
, pp. 1009-1019
-
-
Majeti, R.1
-
16
-
-
84866996937
-
Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
-
Kuo SR, Wong L, Liu JS. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel 2012;25(10):561-9
-
(2012)
Protein Eng des Sel
, vol.25
, Issue.10
, pp. 561-569
-
-
Kuo, S.R.1
Wong, L.2
Liu, J.S.3
-
17
-
-
84900846411
-
A bi-specific T cell engaging monoclonal antibody (mAb) derived from a TCR-like Mab specific for WT1/HLAA0201 (ESKBiTE) shows a potent activity against human AML and Ph+ ALL in mouse models [abstract]
-
Pankov D, Dao T, Wang Y, et al. A bi-specific T cell engaging monoclonal antibody (mAb) derived from a TCR-like Mab specific for WT1/HLAA0201 (ESKBiTE) shows a potent activity against human AML and Ph+ ALL in mouse models [abstract]. Blood 2013;122(21):604
-
(2013)
Blood
, vol.122
, Issue.21
, pp. 604
-
-
Pankov, D.1
Dao, T.2
Wang, Y.3
-
18
-
-
84863522243
-
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
-
Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119(26): 6226-33
-
(2012)
Blood
, vol.119
, Issue.26
, pp. 6226-6233
-
-
Klinger, M.1
Brandl, C.2
Zugmaier, G.3
-
19
-
-
84882782587
-
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
-
Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121(26):5154-7
-
(2013)
Blood
, vol.121
, Issue.26
, pp. 5154-5157
-
-
Teachey, D.T.1
Rheingold, S.R.2
Maude, S.L.3
|